Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11724286 | 0.80 | TSHR (0.39) | TSHRCYP3A4ALDH1A1TDP1ACHE | |
| SCHEMBL1531216 | 0.78 | CYP19A1 (0.38) | TSHRCYP3A4ALDH1A1CYP19A1LMNA | |
| SCHEMBL11730933 | 0.76 | LMNA (0.39) | TSHRCYP3A4ALDH1A1CYP19A1LMNA | |
| SCHEMBL1036242 | 0.76 | ALDH1A1 (0.37) | TSHRALDH1A1TDP1CYP19A1LMNA | |
| SCHEMBL896533 | 0.76 | ALDH1A1 (0.42) | TSHRALDH1A1TDP1HSD17B10CYP19A1 | |
| SCHEMBL6829052 | 0.76 | HTT (0.41) | TSHRCYP3A4ALDH1A1TDP1ACHE | |
| SCHEMBL1034363 | 0.76 | TDP1 (0.41) | TSHRALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL1034794 | 0.72 | PTGS2 (0.39) | ALDH1A1TDP1LMNAMEN1HTT | |
| SCHEMBL7171038 | 0.72 | VCAM1 (0.44) | TSHRALDH1A1TDP1CYP19A1LMNA | |
| SCHEMBL3898476 | 0.72 | TSHR (0.58) | TSHRCYP3A4ALDH1A1TDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-0122109-A2 | Preparation of cyano- or aminoalkyl substituted aromatic amines | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-10-17 | — | — | EP | claimed |
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| EP-1787992-B1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-04-29 | — | — | EP | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0880523-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029109-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
| EP-0628027-A1 | AZO OXIME ETHERS AND THEIR USE AS FUNGICIDES | CIBA-GEIGY AG (CH) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016986-A1 | AZO OXIME ETHERS AND THEIR USE AS FUNGICIDES | CIBA-GEIGY AG (CH) | 1993-09-02 | — | — | WO | disclosed |
| EP-0122109-A2 | Preparation of cyano- or aminoalkyl substituted aromatic amines | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-10-17 | — | — | EP | disclosed |
| US-4005076-A | ANTIBIOTICS | GRUPPO LEPETIT S.P.A. (IT) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TSHR 110/4885CYP3A4 1530/4885ALDH1A1 3674/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | TSHR 333/4885CYP3A4 1450/4885ALDH1A1 3369/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TSHR 247/4885CYP3A4 1112/4885ALDH1A1 2779/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | TSHR 335/4885CYP3A4 1532/4885ALDH1A1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.